Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHF5993 vs Seretide in Adolescent Subjects With Uncontrolled Asthma
NCT07858123Phase 3Not yet recruiting
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Nov 2026
- Primary completion
- Jun 2030
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of beclometasone dipropionate/formoterol fumarate/glycopyrronium in asthma (2 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Forced Expiratory Volume in the first second at 26 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
beclometasone dipropionate/formoterol fumarate/glycopyrronium
03
Conditions
asthma
Beyond the preview
Go deeper on NCT07858123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07858123.